falsefalse

Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer - Episode 5

ADCs and Novel Agents Under Investigation in Advanced Endometrial Cancer

,

Christian Marth, MD, PhD, and John Chan, MD, discuss antibody-drug conjugates and agents under evaluation in endometrial cancer.

Current Time 0:00
Duration 6:32
Loaded: 0%
Stream Type LIVE
Remaining Time 6:32
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Current Treatment Strategies and Challenges in Frontline Advanced Endometrial Cancer
EP. 2: LEAP-001 Data for First-Line Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer
EP. 3: Subgroup Data for Lenvatinib/Pembrolizumab In Frontline Advanced Endometrial Cancer After Perioperative Chemo
EP. 4: The Role of IO/Chemo Combinations in Frontline Advanced/Recurrent Endometrial Cancer
Now Viewing
EP. 5: ADCs and Novel Agents Under Investigation in Advanced Endometrial Cancer
EP. 6: Ongoing Research to Watch in Advanced Endometrial Cancer in 2025

Related Content:

UCSF Helen Diller Family Comprehensive Cancer CenterDiving into Data Trends and Ongoing Research in Advanced Endometrial CancerOncLive News Network®Gynecologic Oncology
Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer
Dr Grisham on the Safety of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer
Ongoing Research to Watch in Ovarian Cancer in 2025
x